TIDES Asia: Oligonucleotide Track
Advance oligonucleotide therapeutics with the chemistry, delivery, and CMC insight needed to move from platform innovation to clinical execution.
From RNAi and antisense to aptamers, RNA editing, mRNA engineering, conjugates, and targeted delivery, the Oligonucleotide Track brings together the science and strategy shaping the next generation of oligonucleotide therapeutics. Designed for teams working across discovery, development, and manufacturing, this track highlights how innovators are improving potency, specificity, tissue reach, and scalability across a rapidly evolving modality.
About the Oligonucleotide Track
The Oligonucleotide Track explores the technologies, case studies, and development strategies driving progress across RNA-based therapeutics. With agenda coverage spanning CNS, ocular, liver, oncology, and immune-related applications, delegates will gain practical insight into how novel chemistry, delivery innovation, translational science, and CMC planning are coming together to accelerate oligonucleotide pipelines.
RNAi and antisense innovation
Discover how developers are improving gene silencing, splice correction, and therapeutic durability while reducing off-target effects.
Conjugates and merged modalities
Explore antibody-oligonucleotide and peptide-oligonucleotide conjugate strategies designed to improve targeting and expand therapeutic reach.
Novel chemistries and chemical modifications
Learn how backbone, seed-region, and other molecular modifications are being used to enhance efficacy, safety, and tolerability.
Targeted and extrahepatic delivery
See how the field is addressing delivery challenges in CNS, ocular, and other extrahepatic tissues through new platforms and formulations.
mRNA and RNA editing platforms
Examine emerging approaches in programmable mRNA modification and RNA editing to improve functional performance and open new therapeutic possibilities.
CMC, scale-up, and regulatory strategy
Gain insight into process safety, manufacturing scale-up, and evolving regulatory expectations, including China-specific CMC considerations.
Industry challenges we’ll address at TIDES Asia
How to improve potency and specificity without increasing off-target effects.
How to expand delivery beyond traditional tissues, especially into CNS, ocular, and extrahepatic settings.
How to translate novel chemistry into clinically relevant performance and tolerability.
How to build platform-based CMC strategies that support multiple programs and conjugate pipelines.
How to manage process safety, technology transfer, and GMP scale-up for increasingly complex oligonucleotide products.
How to navigate evolving regulatory expectations across global markets, including China.
Who will benefit from the oligonucleotide track?
- VP / Head / Director of Oligonucleotide Research
- VP / Head / Director of RNA Therapeutics
- VP / Director of CMC
- Head of Technical Operations
- Director of Process Development
- Director of Analytical Development
- Head of Delivery / Formulation
- Translational Science Lead
- Preclinical Development Lead
- Toxicology Lead
- Regulatory CMC Lead
- Manufacturing Science and Technology Lead